Abstract: Disclosed herein are anti-ABCB5 antibodies possessing superior binding and biological activities, for instance, relative to commercially available ABCB5 antibodies, pharmaceutical compositions comprising such. Also provided herein are therapeutic and diagnostic applications of such anti-ABCB5 antibodies.
Type:
Application
Filed:
April 30, 2021
Publication date:
June 29, 2023
Applicants:
Children's Medical Center Corporation, TICEBA GmbH, RHEACELL GmbH & Co., KG
Inventors:
Markus H. Frank, Christoph Ganss, Christoph Maßlo, Mark Andreas Kluth, Jan Reckenbeil
Abstract: Methods and compositions comprising ABCB5+ stem cell to treat hyper-inflammatory disorders, such as acute respiratory distress syndrome (ARDS) are provided. Such compositions may be used to treat, for example, patients with severe COVID19.
Type:
Application
Filed:
March 30, 2021
Publication date:
May 11, 2023
Applicants:
Children's Medical Center Corporation, TICEBA GmbH
Inventors:
Mark Andreas Kluth, Markus H. Frank, Christoph Ganss
Abstract: Populations of synthetic ABCB5+ stem cells, wherein greater than 96.8% of the population is an in vitro progeny of physiologically occurring skin-derived ABCB5? positive mesenchymal stem cells are provided. Also provided are methods of making the synthetic cells and methods of use thereof.
Type:
Application
Filed:
March 27, 2020
Publication date:
June 16, 2022
Applicants:
Children's Medical Center Corporation, TICEBA GmbH
Inventors:
Markus H. Frank, Mark Andreas Kluth, Christoph Ganss
Abstract: Populations of synthetic ABCB5+ stem cells, wherein greater than 96.8% of the population is an in vitro progeny of physiologically occurring skin-derived ABCB5-positive mesenchymal stem cells are provided. Also provided are methods of making the synthetic cells and methods of use thereof.
Type:
Application
Filed:
March 30, 2020
Publication date:
April 1, 2021
Applicants:
Children's Medical Center Corporation, TICEBA GmbH
Inventors:
Markus H. Frank, Andreas Kluth, Christoph Ganss